Neurizon Therapeutics Limited has released a press release.
Canine Trial Update
Filed with ASX ·
On 6ix: 6ix.com/news/canine-trial-update
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Results show MPL suppresses biomarkers associated with MND
- Louie the Beagle surpasses one year on MPL
- MND Biomarkers and Pharmacodynamics Results
- Motor Neurone Disease Phase 1/2 Clinical Trial Update
- PharmAust MND Trial Interim Analysis PK Outcomes
Later from Neurizon Therapeutics
- MND Trial Successfully Completes 3rd Patient Cohort
- Epichem enters voluntary liquidation
- Cohort 3 Pharmacokinetics in MND Patients Completed
- Additional Phase 1 data suggest MPL may inhibit MND
- Chief Executive Officer Appointment
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics